REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.225 (2.28%)
Spread: 0.80 (8.247%)
Open: 9.875
High: 10.10
Low: 9.875
Prev. Close: 9.875
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

Mon, 05th Feb 2024 14:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ECR Minerals PLC - Australia-focused gold exploration company - Drills seven successful holes, and says there is evidence of anomalous gold with the best result being 23.39 grammes per tonne of gold over metre. Says the best sample still has 4.7 g/t of gold in the tailings of the initial results. Chief Executive Officer Mike Whitlow says: "This is an encouraging start to our examination of Davey Road. Based on ECR's work historically in this region, our expectation was that any gold would be both course and confined within narrow veins. These preliminary results support this assumption and consequently analysis of the bulk samples is a necessary step before we have a full picture of the geology. There is plenty so far to be pleased with but these results are indicative only and we look forward to gaining a better understanding of the location once full testing is complete."

----------

FireAngel Safety Technology Group PLC - Coventry, England-based developer and supplier of home safety products - Expects to report sales for 2023 of approximately GBP41.0 million, down 29% from GBP57.5 million a year ago. Says UK Trade division performance suffered from the restructuring in its sales team. International sales also remained comparatively depressed in the second half of 2023, it says, as new legislation in Benelux in 2022, which had led to a surge in customer demand in the region for products during 2022, was not carried into 2023 as customers looked to reduce inventory intake.At December 31, FireAngel had net debt of GBP3.1 million, down from GBP4.8 million in 2022.

----------

Smarttech247 Group PLC - Cork, Ireland-based artificial intelligence-enhanced cybersecurity services provider - Expands its NoPhish email security tool to Google Mail users. Says NoPhish employs advanced analysis algorithms to evaluate the content and legitimacy of the reported emails, offering instant feedback to the user. In cases where an email is identified as suspicious or malicious, NoPhish takes proactive measures by automatically removing the email from the user's inbox, thereby mitigating the risk of accidental exposure to harmful content. CEO Raluca Saceanu says: "We are delighted to bring NoPhish to Google Mail users. Our mission has always been to provide cutting-edge, user-friendly cybersecurity tools and by making NoPhish available on one of the world's most widely used email platforms, we are taking a significant step towards making the digital world safer for everyone. The integration signifies major advancement in email security, as Google Mail's extensive user base can now benefit from Smarttech247's phishing detection and response technology. This expansion is part of our ongoing efforts to adapt and evolve in the face of ever-changing cyber threats, ensuring users across various platforms can enjoy a safer email experience."

----------

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious diseases - Says Sally Adams resigns as chief development officer, while Callum Scott is named as the new head of development, effective immediately. Says Adams will remain with the company part time for six months to ensure a "smooth and effective transition of responsibilities."

According to Scancell, Scott has more than 15 years of experience in vaccine research and development. Previously, he held the role of technical transfer & formulation development manager at biotech firm Allergy Therapeutics PLC. CEO Lindy Durrant says: "Firstly, on behalf of the Scancell board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the board and leading clinical development. She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future. "I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."

----------

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Appoints Camillo Pane as chair, effective February 19. He will be replacing Jo LeCouilliard. "Jo and the board feel that it is now appropriate for her to step down from the board and to appoint a new chair, with strong international consumer healthcare experience, to lead the company through its next strategic phase, focusing on organic growth through marketing and innovation," says Alliance Pharma. Senior Independent Director Richard Jones says: "On behalf of the Alliance board and the company I would like to thank Jo for her significant contribution to Alliance over the past five years and wish her well for the future. We look forward to Camillo joining the board as chair and harnessing his wide-ranging consumer healthcare experience to further enhance and develop our group strategy. In the meantime, the board remains focused on creating value for our shareholders by investing in growth whilst carefully managing our cost base."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2019 11:19

Scancell gets go-ahead for UK second phase trials of 'SCIB1'

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings has received all of the UK regulatory, ethical and legal approvals required to initiate the phase 2 clinical trial to assess the safety and efficacy of 'SCIB1' in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda), it announced on Thursday.

Read more
8 Apr 2019 11:34

Scancell Holdings expands IP protection with Japanese patent

(Sharecast News) - Scancell Holdings on Monday won a Japanese patent for its Moditope immunotherapy platform, which stimulates the production of cells that overcome the immune suppression induced by tumours.

Read more
8 Apr 2019 11:27

Scancell Gets Japan Patent Protecting Moditope Immunotherapy Platform

LONDON (Alliance News) - Scancell Holdings PLC on Monday said the Japanese Patent Office has granted a patent providing protection for its Moditope immunotherapy platform.The cancer said T

Read more
20 Mar 2019 13:38

Scancell Holdings Gets Further Patent Protection In US And Europe

LONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC has received a new patent for its Modi-1 drug candidate in the US, it said on Wednesday.The patent, granted by the US in in

Read more
31 Jan 2019 13:59

Loss Widens As Scancell Continues Moditope Cancer Vaccine Development

LONDON (Alliance News) - Scancell Holdings PLC on Thursday said its loss widened in the first half of its year on mounting administrative expenses as its development of Moditope in Scancell were a

Read more
31 Jan 2019 09:48

Scancell shares slip as losses widen in first half

(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.

Read more
23 Jan 2019 11:20

Scancell loses out on Cancer Research UK grant

(Sharecast News) - Immunotherapies developer Scancell has seen Cancer Research UK pass on its submission into the Grand Challenge research initiative.

Read more
23 Jan 2019 10:41

WINNERS & LOSERS SUMMARY: Metro Bank Slumps 29% On Annual Profit Miss

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 1.9%. The airline was extending gains a

Read more
23 Jan 2019 10:18

Scancell Cancer Vaccine Project Misses Out On Cancer Research UK Grant

LONDON (Alliance News) - Scancell Holdings PLC said Wednesday its Project Blueprint proposal was not selected for the Cancer Research UK Grand Challenge grant.Shares in Scancell were down -

Read more
21 Jan 2019 12:58

Scancell Appoints New Head Of Research And Manufacturing Divisions

LONDON (Alliance News) - Scancell Holdings PLC on Monday said it appointed two new executives as head of research and head of manufacturing.Samantha Paston joined Scancell as head of in She

Read more
21 Jan 2019 12:30

Scancell appoints new heads of research and manufacturing

(Sharecast News) - Immunotherapy developer Scancell Holdings announced the appointment of Dr Samantha Paston as its head of research, and Dr Adrian Parry as its head of manufacturing, on Monday.

Read more
30 Oct 2018 16:33

Scancell Holdings Reports Tumour Rejection Data In Cancer Vaccine

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that data from its second vaccine from its Moditope platform, Modi-2, showed T-cell response, tumour rejection and increased survival in

Read more
30 Oct 2018 14:36

Scancell pleased with progress on 'Moditope' vaccines

(Sharecast News) - Novel immunotherapies developer Scancell Holdings updated the market on the development of its second vaccine from its proprietary 'Moditope' platform, Modi-2, on Tuesday, reporting that pre-clinical data demonstrated that homocitrullinated peptides induced highly potent T-cell responses, tumour rejection and increased survival in murine models.

Read more
24 Oct 2018 12:28

Oxford Technology VCTs Mostly Report Drop In Net Asset Value

LONDON (Alliance News) - The Oxford Technology-managed venture capital trusts reported interim results on Wednesday, with all but one see a drop in net asset value.Oxford Technology Venture

Read more
24 Oct 2018 10:43

WINNERS & LOSERS SUMMARY: Metro Bank Down Amid Mortgage Competition

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 0.9%. The bank reported a rise in third by

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.